Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
Clinical trial NCT02839681 · TERMINATED
Trial details
- NCT number
- NCT02839681
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-19
- Primary completion
- 2018-06-12
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.